SCHEMBL7130677

SCHEMBL7130677

COc1ccc(C2CC2N(C(=O)O)C(C)(C)C)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.45
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
HTR2C P28335 1/20 0.43
DRD2 P14416 1/20 0.41
OPRM1 P35372 1/20 0.41
DRD3 P35462 1/20 0.41
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
MAPT P10636 1/20 0.40
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 2/20 0.39
SLC6A3 Q01959 2/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
EDNRB P24530 1/20 0.38
EDNRA P25101 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7446687 1.00 KDM1A (0.45) KDM1AMAOAMAOBHTR2CDRD2
SCHEMBL14841626 0.84 KDM1A (0.38) KDM1AMAOADRD2OPRM1DRD3
SCHEMBL1524298 0.84 KDM1A (0.38) KDM1AMAOADRD2OPRM1DRD3
SCHEMBL1029212 0.83 MAOA (0.46) KDM1AMAOAMAOBHTR2CDRD3
SCHEMBL1029213 0.83 MAOA (0.46) KDM1AMAOAMAOBHTR2CDRD3
SCHEMBL7132779 0.82 DRD2 (0.44) HTR2CDRD2OPRM1DRD3SLC6A2
SCHEMBL7132775 0.82 DRD2 (0.44) HTR2CDRD2OPRM1DRD3SLC6A2
SCHEMBL17550723 0.82 MAOA (0.35) KDM1AMAOADRD2OPRM1DRD3
SCHEMBL17960615 0.82 MAOA (0.37) KDM1AMAOAMAOBDRD2OPRM1
SCHEMBL2215832 0.82 KDM1A (0.40) KDM1AMAOAMAOBHTR2CSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1296938-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE Pfizer Limited (GB) 2003-04-02 EP disclosed
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER, INC. 2002-05-02 US disclosed
WO-2002002513-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE PFIZER LIMITED (GB) 2002-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase ENGASE, ENPEP, CPN1 KDM1A 1587/4885MAOA 383/4885MAOB 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.